← Back to Browse

ImageneBio Inc

IMA • Healthcare

5
Grade F
Compass
Current Price
$5.77
Market Cap
$69M

About ImageneBio Inc

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

Quality Assessment

ImageneBio Inc is a high-risk healthcare company with a Compass Score of 5. This stock has poor quality metrics and high risk. Not recommended for conservative investors.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Technical Overview

Click any metric for details

Wall Street View

Consensus
N/A
Analysts
3
Price Target
🔒
Upside
🔒

Growth Projections

Projected EPS Growth
🔒
Projected Revenue Growth
🔒

Financial Health

Click any metric for details

Similar High-Quality Stocks

MASS

908 Devices Inc.

20
$7.54
Grade D

NEOG

Neogen Corporation

20
$8.69
Grade D

ESTA

Establishment Labs Holdings Inc.

20
$69.08
Grade D

CCM

Concord Medical Services Holdings Limited

20
$5.35
Grade D

OGI

Organigram Global Inc.

20
$1.11
Grade D

SNDA

Sonida Senior Living, Inc.

20
$38.78
Grade D

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.